Filing Details
- Accession Number:
- 0001562180-17-000081
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-01-03 16:02:15
- Reporting Period:
- 2017-01-03
- Filing Date:
- 2017-01-03
- Accepted Time:
- 2017-01-03 16:02:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1517022 | Akebia Therapeutics Inc. | AKBA | Pharmaceutical Preparations (2834) | 208756903 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1591098 | Duane Nash | C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2017-01-03 | 1,980 | $10.46 | 25,668 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- 47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date.
- Shares sold by reporting person pursuant to a 10b5-1 plan in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1.
- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.42 to $10.58, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.